Condition: Stage III Cutaneous Melanoma AJCC v7 · Stage IV Cutaneous Melanoma AJCC v6 and v7 · Unresectable Melanoma · Sponsor: National Cancer Institute (NCI)
This phase II trial compares the effect of dabrafenib and trametinib given continuously to given with a break in treatment (intermittent) in treating patients with stage III-IV melanoma that cannot be removed by surgery and contains a B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving dabrafenib and trametinib with intermittent dosing may be as effect as when given continuously in treating patients with stage III-IV melanoma with a BRAF mutation that cannot be removed by surgery.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | — |
| Anchorage Associates in Radiation Medicine | Anchorage, Alaska, United States | — |
| Anchorage Radiation Therapy Center | Anchorage, Alaska, United States | — |
| Alaska Breast Care and Surgery LLC | Anchorage, Alaska, United States | — |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | — |
| Alaska Regional Hospital | Anchorage, Alaska, United States | — |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | — |
| Anchorage Oncology Centre | Anchorage, Alaska, United States | — |
| Katmai Oncology Group | Anchorage, Alaska, United States | — |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | — |
| Fairbanks Memorial Hospital | Fairbanks, Alaska, United States | — |
| Banner University Medical Center - Tucson | Tucson, Arizona, United States | — |
+ 741 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.